ArticleScientific reports2026
A novel role of erythropoietin in skin pigmentation through melanin production.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Melanin protects the skin from UV radiation and oxidative stress. Its synthesis in melanocytes is regulated by α-MSH and the Melanocortin 1 Receptor signaling pathway. The erythropoietin receptor (EPOR) is expressed in melanocytes; however, its function is unknown. EPOR is a receptor for erythropoietin (EPO), which promotes hematopoiesis and protection from hypoxic stress. We hypothesized that EPOR is involved in pigment regulation. Mouse skin tissue models, cultured melanocytes, and human-derived artificial skin models were treated with recombinant human EPO (rhEPO) and/or EPO-derived peptides, and examined changes in pigmentation and cell signaling pathways. rhEPO significantly increased pigmentation, induced ERK and AKT phosphorylation, and increased tyrosinase expression in mouse melanocytes. Some EPO-derived peptides increased pigmentation in an artificial human skin model. Our results indicate that EPOR activation acts as a regulator of melanin synthesis and suggest that EPOR agonists have potential for the treatment of pigment-related diseases as well as cosmetic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.